Are GLP-1s on the verge of becoming pharma’s biggest segment? Yes and no. It depends whether you’re watching products or categories. And in terms of individual drugs, it likely depends on the year. Oncology is still on top for now. On the product level, according to Evaluate’s 2028 projections, Keytruda will maintain its lead at… The post Are GLP-1s about to dethrone oncology as pharma’s biggest segment? Not for a few years yet appeared first on Drug Discovery and Development.
